Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News EOM Pharmaceutical Holdings Inc IMUC

Healthcare Biotechnology
EOM Pharmaceutical Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing novel drugs for patients suffering from debilitating and deadly diseases, including infectious diseases; autoimmune diseases including rheumatoid arthritis; and cachexia associated with acquired immune deficiency syndrome (AIDS) and cancer. It has two pipeline assets in their... see more

Recent & Breaking News (PINL:IMUC)

ImmunoCellular Therapeutics to Present at ROTH Conference on March 10th

PR Newswire March 3, 2015

ImmunoCellular Therapeutics to Report 2014 Financial Results on March 9, 2015; a Business Update Conference Call and Webcast is Scheduled for March 12, 2015

PR Newswire March 2, 2015

ImmunoCellular Therapeutics Strengthens Executive Management Team with Appointment of Dr. Steven Swanson to Lead Stem-to-T-Cell Program

PR Newswire February 18, 2015

ImmunoCellular Therapeutics, Ltd. Announces Pricing of a Public Offering of Common Stock and Warrants

PR Newswire February 12, 2015

ImmunoCellular Therapeutics to Present at the BIO CEO & Investor Conference on February 9, 2015

PR Newswire January 28, 2015

ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine

PR Newswire December 17, 2014

ImmunoCellular Therapeutics Receives Positive Regulatory Feedback from European Medicines Agency on Advancing ICT-107 to Phase III Program

PR Newswire December 1, 2014

ImmunoCellular Therapeutics Presents Updated ICT-107 Phase II Data at the Society for Neuro-Oncology Annual Meeting 2014

PR Newswire November 14, 2014

ImmunoCellular Therapeutics Announces Third Quarter 2014 Financial Results

PR Newswire November 10, 2014

ImmunoCellular Therapeutics to Present at Livingston Securities Conference on October 1, 2014

PR Newswire September 26, 2014

ImmunoCellular Therapeutics Expands Cancer Immunotherapy Platform with Antigen-Specific T-cell Technology Licensed from Caltech

PR Newswire September 24, 2014

ImmunoCellular Therapeutics Receives Positive Regulatory Feedback on ICT-107 Supporting Advancement to Registrational Phase III Testing in Newly Diagnosed Glioblastoma

PR Newswire September 17, 2014

ImmunoCellular Therapeutics Announces Second Quarter 2014 Financial Results

PR Newswire August 7, 2014

ImmunoCellular Therapeutics to Report Financial Results for the Second Quarter 2014 on August 7, 2014

PR Newswire July 29, 2014

Theralase's Cancer Technology Demonstrates Vaccine-Like Properties

Accesswire June 16, 2014

How the Lack of R&D at Big Pharma Is Boosting Small Biotechs

Equities.com June 14, 2014

Biotech Investors Need to Focus on Catalysts

Equities.com June 11, 2014

ImmunoCellular Therapeutics Presents Updated ICT-107 Phase II Data in Patients with Newly Diagnosed Glioblastoma at the 2014 ASCO Annual Meeting

PR Newswire June 1, 2014

ImmunoCellular Therapeutics Announces First Quarter 2014 Financial Results

PR Newswire May 8, 2014

ImmunoCellular Therapeutics to Report Financial Results for the First Quarter 2014 on May 8, 2014

PR Newswire May 1, 2014